Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1
Lexicon (LXRX) delivered earnings and revenue surprises of +100.00% and +141.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?